Filter
Reset all

Subjects

Content Types

Countries

Data access

Data access restrictions

Database access

Database licenses

Data licenses

Data upload

Data upload restrictions

Enhanced publication

Institution responsibility type

Institution type

Keywords

Metadata standards

PID systems

Provider types

Quality management

Repository languages

Software

Repository types

Versioning

  • * at the end of a keyword allows wildcard searches
  • " quotes can be used for searching phrases
  • + represents an AND search (default)
  • | represents an OR search
  • - represents a NOT operation
  • ( and ) implies priority
  • ~N after a word specifies the desired edit distance (fuzziness)
  • ~N after a phrase specifies the desired slop amount
  • 1 (current)
Found 3 result(s)

Global Catalogue of Microorganisms

GCM

Subject(s)
Content type(s)
Country
WFCC Global Catalogue of Microorganisms (GCM) is expected to be a robust, reliable and user-friendly system to help culture collections to manage, disseminate and share the information related to their holdings. It also provides a uniform interface for the scientific and industrial communities to access the comprehensive microbial resource information.

National Genomics Data Center

国家基因组科学数据中心

Subject(s)
Content type(s)
Country
The National Genomics Data Center (NGDC), part of the China National Center for Bioinformation (CNCB), advances life & health sciences by providing open access to a suite of resources, with the aim to translate big data into big discoveries and support worldwide activities in both academia and industry.

Coronavirus Antiviral Research Database

COVDB

Subject(s)
Content type(s)
Country
The Coronavirus Antiviral Research Database is designed to expedite the development of SARS-CoV-2 antiviral therapy. It will benefit global coronavirus drug development efforts by (1) promoting uniform reporting of experimental results to facilitate comparisons between different candidate antiviral compounds; (2) identifying gaps in coronavirus antiviral drug development research; (3) helping scientists, clinical investigators, public health officials, and funding agencies prioritize the most promising compounds and repurposed drugs for further development; (4) providing an objective, evidenced-based, source of information for the public; and (5) creating a hub for the exchange of ideas among coronavirus researchers whose feedback is sought and welcomed. By comprehensively reviewing all published laboratory, animal model, and clinical data on potential coronavirus therapies, the Database makes it unlikely that promising treatment approaches will be overlooked. In addition, by making it possible to compare the underlying data associated with competing treatment strategies, stakeholders will be better positioned to prioritize the most promising anti-coronavirus compounds for further development.